NDH.com

icon


Wolters Kluwer | Lippincott Williams & Wilkins
Drug Updates | New Indications
orange bar


   Web Toolkit

   Drug Updates
       New Drugs
       New Indications
   Patient Teaching

   News Capsules

   Drug Warnings

   Herbal Spotlight

   Drug Info and
   Nursing Links


   CE Tests

   Career Opportunities

   Drug Info Bookstore

   Feedback

   Registration

   Disclaimer



paliperidone
Invega Pharmaceutical company:
Ortho-McNeil-Janssen Pharmaceuticals, Inc.
www.invega.com

NEW INDICATION & DOSAGE
Monotherapy or adjunct to mood stabilizers, antidepressants, or both for acute treatment of schizoaffective disorder—
Adults: 6 mg P.O. daily, in the morning. Adjust dosage in 3-mg increments at more than 4-day intervals according to patient response; recommended dosage range, 3 to 12 mg daily.
ADJUST-A-DOSE: If creatinine clearance is 79 ml/minute to 50 ml/minute, initially give 3 mg P.O. once daily. May increase dose to a maximum of 6 mg once daily as tolerated, based on clinical response. If creatinine clearance is 49 ml/minute to 10 ml/minute, initially give 1.5 mg P.O. once daily, increase to maximum dose of 3 mg once daily, as tolerated. Drug isn't recommended in patients with a creatinine clearance less than 10 ml/minute.

     
   

Home - Guest Registry - Customer Service

Brought to you by Lippincott Williams & Wilkins.
For help on how you should use this site, see our
Disclaimer .

© Copyright 2010 by Lippincott Williams & Wilkins